Develops drugs for idiopathic pulmonary fibrosis and acute myeloid leukemia.
Dec 2024Revenue $4.83M/yrExpenses $141M/yr
No trendCash runway ≈ 2.1 years from Dec 2024
Figures by year
When will PureTech Health be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was $4.83M and expenses $141M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $4.83M | $141M | −$136M |
| Dec 2023 | $3.33M | $150M | −$146M |
| Dec 2022 | $15.6M | $213M | −$198M |
| Dec 2021 | $17.4M | $168M | −$150M |
| Dec 2020 | $11.8M | $131M | −$120M |
| Dec 2019 | $9.81M | $145M | −$135M |
| Dec 2018 | $20.7M | $125M | −$104M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.